Get the app!
Back to Trades
Sell4

MADRIGAL PHARMACEUTICALS, INC.

MDGL

Total Value
$17.5M
Net $16.6M sold
Sales
$16.6M
12 transactions

Company Information

Ticker Symbol
MDGL
CIK
0001157601

Insider Information

Role
Director
Director
Location
WEST CONSHOHOCKEN, PA

Filing Details

Filing Date
Aug 13, 2025
Transaction Date
Aug 11, 2025
Accession Number
0001236927-25-000005
Form Type
4
Net Trading Amount
-$16.6M

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Aug 11, 2025Common Stock3,203$9.45Exercise$30.3K
Aug 11, 2025Common Stock2,903$350.19Sale$1.0M
Aug 11, 2025Common Stock300$351.04Sale$105.3K
Aug 12, 2025Common Stock43,605$9.45Exercise$412.1K
Aug 12, 2025Common Stock3,303$350.93Sale$1.2M
Aug 12, 2025Common Stock3,202$351.59Sale$1.1M
Aug 12, 2025Common Stock1,382$352.61Sale$487.3K
Aug 12, 2025Common Stock4,768$354.06Sale$1.7M
Aug 12, 2025Common Stock6,546$355.00Sale$2.3M
Aug 12, 2025Common Stock5,244$355.97Sale$1.9M
Aug 12, 2025Common Stock5,094$356.94Sale$1.8M
Aug 12, 2025Common Stock8,434$357.93Sale$3.0M
Aug 12, 2025Common Stock5,032$358.83Sale$1.8M
Aug 12, 2025Common Stock600$359.81Sale$215.9K

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Aug 11, 2025Derivative3,203$9.45Exercise$30.3K
Aug 12, 2025Derivative43,605$9.45Exercise$412.1K

Footnotes

  1. (F1)These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
  2. (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  3. (F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.24, inclusive.
  4. (F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.16 to $351.14, inclusive.
  5. (F5)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.16 to $352.12, inclusive.
  6. (F6)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.48 to $353.47, inclusive.
  7. (F7)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.48 to $354.47, inclusive.
  8. (F8)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.48 to $355.47, inclusive.
  9. (F9)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.48 to $356.46, inclusive.
  10. (F10)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.48 to $357.46, inclusive.
  11. (F11)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.48 to $358.47, inclusive.
  12. (F12)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.48 to $359.41, inclusive.
  13. (F13)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.78 to $359.87, inclusive.
  14. (F14)The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  15. (F15)The shares underlying this stock option are fully vested and exercisable.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.